-2.30%
3.78%
-4.27%
-17.27%
-37.51%
47.09%
296.91%
AI Spotlight on CYTK
Company Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy.
The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial.Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc.The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Market Data
| Last Price | 48.82 |
| Change Percentage | -2.30% |
| Open | 49.68 |
| Previous Close | 49.97 |
| Market Cap ( Millions) | 5761 |
| Volume | 452532 |
| Year High | 84.05 |
| Year Low | 44.49 |
| M A 50 | 49.04 |
| M A 200 | 54.5 |
Financial Ratios
| FCF Yield | -7.07% |
| Dividend Yield | 0.00% |
| ROE | 335.19% |
| Debt / Equity | -5676.27% |
| Net Debt / EBIDTA | -153.35% |
| Price To Book | -413.01 |
| Price Earnings Ratio | -9.97 |
| Price To FCF | -14.15 |
| Price To sales | 1789.82 |
| EV / EBITDA | -13.43 |
News
- Jan -30 - Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm
- Jan -30 - Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program
- Jan -23 - CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study
- Jan -22 - Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
- Jan -21 - Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction
- Jan -13 - Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
- Jan -06 - Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Jan -03 - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Dec -31 - Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution
- Dec -23 - Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
- Dec -20 - Why Cytokinetics Stock Was a Nearly 5% Winner Today
- Dec -20 - Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
- Dec -09 - Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?
- Dec -04 - Cytokinetics Initiates Confirmatory Study on Heart Failure Drug
- Dec -03 - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dec -03 - FDA Accepts Cytokinetics' Application for Cardiovascular Drug
- Dec -03 - Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
- Dec -02 - Cytokinetics to Participate in December Investor Conferences
- Dec -02 - Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
- Nov -20 - Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Muscle Activators
Expected Growth : 9.27 %
What the company do ?
Muscle Activators from Cytokinetics, Incorporated are novel, small molecule drugs that selectively activate the fast skeletal muscle troponin complex, leading to increased muscle contraction force.
Why we expect these perspectives ?
Cytokinetics' Muscle Activators, with 9.27% growth, is driven by increasing adoption in rare muscle disorders, strong clinical trial results, and expanding partnerships. Growing demand for novel treatments in neuromuscular diseases, such as spinal muscular atrophy and amyotrophic lateral sclerosis, also contributes to this growth.
Cytokinetics, Incorporated Products
| Product Range | What is it ? |
|---|---|
| Omnecartil | Omnecartil is a cardiac myosin activator that increases cardiac contractility and is being developed for the treatment of heart failure. |
| CK-3773274 | CK-3773274 is a next-generation cardiac myosin inhibitor that reduces cardiac contractility and is being developed for the treatment of hypertrophic cardiomyopathy (HCM). |
| CK-274 | CK-274 is a cardiac myosin inhibitor that reduces cardiac contractility and is being developed for the treatment of hypertrophic cardiomyopathy (HCM). |
| CK-136 | CK-136 is a cardiac troponin activator that increases cardiac contractility and is being developed for the treatment of heart failure. |
| CK-107 | CK-107 is a fast skeletal muscle troponin activator that increases muscle force and is being developed for the treatment of spinal muscular atrophy (SMA) and other neuromuscular diseases. |
Cytokinetics, Incorporated's Porter Forces
Threat Of Substitutes
Cytokinetics, Incorporated has a moderate threat of substitutes due to the availability of alternative treatments for cardiovascular and muscle disorders.
Bargaining Power Of Customers
Cytokinetics, Incorporated has a low bargaining power of customers due to the lack of negotiating power of individual patients and the high demand for effective treatments.
Bargaining Power Of Suppliers
Cytokinetics, Incorporated has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and the company's dependence on a few key suppliers.
Threat Of New Entrants
Cytokinetics, Incorporated has a high threat of new entrants due to the attractiveness of the pharmaceutical industry and the ease of entry for new companies with innovative technologies.
Intensity Of Rivalry
Cytokinetics, Incorporated operates in a highly competitive industry with many established players, leading to a high intensity of rivalry among companies.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 255.14% |
| Debt Cost | 7.56% |
| Equity Weight | -155.14% |
| Equity Cost | 7.56% |
| WACC | 7.56% |
| Leverage | -164.46% |
Cytokinetics, Incorporated : Quality Control
Cytokinetics, Incorporated passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, … |
| SRPT | Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It … |
| BMRN | BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment … |
| AGIO | Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) … |
| SWTX | SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Agios Pharmaceuticals
A-Score
1-Year Total Return ->
🥈
BioMarin Pharmaceutical
A-Score
1-Year Total Return ->
🥉
Crinetics Pharmaceuticals
A-Score
1-Year Total Return ->
4
Sarepta Therapeutics
A-Score
1-Year Total Return ->
5
Cytokinetics
A-Score
1-Year Total Return ->
6
